Skip to content

Bone Healing in Immediate Dental Implants

Effect of PRP on Bone Healing in Immediate Implants Analyzed by CBCT

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04650763
Enrollment
12
Registered
2020-12-03
Start date
2017-10-02
Completion date
2018-03-30
Last updated
2020-12-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alveolar Bone Loss, Platelet Rich Plasma

Keywords

Dental implant, Cone Beam Computerized Tomography (CBCT).

Brief summary

To study the effect of platelet-rich plasma concentrate on marginal bone loss and bone mineral density in immediate implant placement through CBCT.

Detailed description

12 subjects were equally categorized into two groups. Group, I was the control group; whereas, the subjects in Group II received Platelet Rich Plasma (PRP) therapy. All subjects were given a standard treatment with single implant system. Inserted implants were analyzed through Cone Beam Computerized Tomography (CBCT). Records were registered at the baseline, at 12th week before functional loading and 26th week after functional loading.

Interventions

BIOLOGICALPRP injection

PRP was prepared using patient's blood and mixed with saline or mixture of calcium chloride and thrombin to form a liquid solution; in order to inject at the surgical site after placement of implant.

DEVICEAutomated blood cell separator to extract PRP

Blood was withdrawn from antecubital vein and mixed with anticoagulant. Blood sample was then centrifuged to obtain platelet rich plasma which was injected at surgical site after implant placement.

Sponsors

CMH Lahore Medical College and Institute of Dentistry
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
20 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

* patients maintaining good oral hygiene, having adequate bone quantity at the implant site, uneventful extraction

Exclusion criteria

* Active infection around implant site, immunocompromised state, with current major systemic disease (uncontrolled diabetes, rheumatoid arthritis, etc.) or oral pathologies, history of bleeding disorders or on anticoagulant therapy, or patients on bisphosphonates were excluded from the study

Design outcomes

Primary

MeasureTime frameDescription
Measurement of bone loss at baseline (12 weeks) and later at 26weeksBaseline -before functional loading at 12 weeks & at 26 weeks- after functional loading to assess changes in marginal bone loss in sagittal view using CBCTMeasurement at mesial in mm

Secondary

MeasureTime frameDescription
Measurement of bone loss at baseline (12 weeks) and later at 26weeksBaseline -before functional loading at 12 weeks & at 26 weeks- after functional loading to assess changes in marginal bone loss in sagittal view using CBCTMeasurement at distal in mm

Other

MeasureTime frameDescription
Bone Mineral DensityBaseline -before functional loading at 12 weeks & at 26 weeks- after functional loading to assess changes in marginal bone loss in sagittal view using CBCTMeasurement in Hounsfield number

Countries

Pakistan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 16, 2026